Literature DB >> 7812598

Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle.

M Tonini1, E Messori, G P Franceschetti, C A Rizzi, A F Castoldi, T Coccini, S M Candura.   

Abstract

In human isolated detrusor strips, submaximal contractile responses evoked by electrical stimulation were resistant to hexamethonium (30 microM) and abolished by tetrodotoxin (0.6 microM) and hyoscine (1 microM), indicating the activation of postganglionic cholinergic nerves. In methysergide (1 microM) and ondansetron (3 microM) pretreated tissues, 5-hydroxytryptamine (5-HT) (0.3 nM-1 microM) caused a concentration-dependent increase in the amplitude of contractions (pEC50 = 8.1), which was antagonized by the selective 5-HT4 receptor antagonist GR 113808 (3, 10 and 30 nM) in a competitive manner. Schild analysis yielded a pA2 estimate of 8.9, a value comparable to that reported for GR 113808 in other animal and human peripheral tissues (8.8-9.7). Our findings indicate that neuromuscular cholinergic transmission in human isolated detrusor muscle is facilitated by neural 5-HT receptors belonging to the 5-HT4 subtype. The human urinary bladder can thus be regarded as an additional site in which 5-HT4 receptors are distributed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7812598      PMCID: PMC1510065          DOI: 10.1111/j.1476-5381.1994.tb16163.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

Review 1.  Novel enteric 5-HT4 receptors and gastrointestinal prokinetic action.

Authors:  M Tonini; C A Rizzi; L Manzo; L Onori
Journal:  Pharmacol Res       Date:  1991-07       Impact factor: 7.658

Review 2.  The 5-HT4 receptor.

Authors:  A P Ford; D E Clarke
Journal:  Med Res Rev       Date:  1993-11       Impact factor: 12.944

3.  Blockade of human atrial 5-HT4 receptors by GR 113808.

Authors:  A J Kaumann
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder.

Authors:  M Corsi; C Pietra; G Toson; D Trist; G Tuccitto; W Artibani
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

5.  GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.

Authors:  J D Gale; C J Grossman; J W Whitehead; A W Oxford; K T Bunce; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

6.  Evidence for an inhibitory 5-HT4 receptor in urinary bladder of rhesus and Cynomolgus monkeys.

Authors:  M V Waikar; A P Ford; D E Clarke
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

7.  Influence of serotonin on lower urinary tract smooth muscle in vitro.

Authors:  P Klarskov; J Hørby-Petersen
Journal:  Br J Urol       Date:  1986-10

8.  Further studies on the motor response of the human isolated urinary bladder to tachykinins, capsaicin and electrical field stimulation.

Authors:  C A Maggi; R Patacchini; P Santicioli; D Turini; G Barbanti; P Beneforti; P Rovero; A Meli
Journal:  Gen Pharmacol       Date:  1989
  8 in total
  22 in total

1.  Characterization of the 5-hydroxytryptamine receptors mediating contraction in the pig isolated intravesical ureter.

Authors:  Medardo Hernández; María Victoria Barahona; Ulf Simonsen; Paz Recio; Luis Rivera; Ana Cristina Martínez; Albino García-Sacristán; Luis M Orensanz; Dolores Prieto
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

2.  The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. A randomized, double-blind, placebo-controlled study.

Authors:  Alberto P Madeiro; Andréa C Rufino; Marair G F Sartori; Edmund C Baracat; Geraldo Rodrigues De Lima; Manoel J B C Girão
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-06-14

Review 3.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

Review 4.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.

Authors:  R M Eglen; D W Bonhaus; L G Johnson; E Leung; R D Clark
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 6.  Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.

Authors:  F De Ponti; M Tonini
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.

Authors:  B Darblade; D Behr-Roussel; D Gorny; T Lebret; G Benoit; J-P Hieble; D Brooks; L Alexandre; F Giuliano
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

8.  Differences in response to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle.

Authors:  F S Tam; K Hillier; K T Bunce; C Grossman
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion.

Authors:  Yogesh Bhattarai; Brianna B Williams; Eric J Battaglioli; Weston R Whitaker; Lisa Till; Madhusudan Grover; David R Linden; Yasutada Akiba; Karunya K Kandimalla; Nicholas C Zachos; Jonathan D Kaunitz; Justin L Sonnenburg; Michael A Fischbach; Gianrico Farrugia; Purna C Kashyap
Journal:  Cell Host Microbe       Date:  2018-06-13       Impact factor: 21.023

Review 10.  Benefit-risk assessment of tegaserod in irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.